New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis

Aaron L. Baggish; Roland R. J. van Kimmenade; Yigal Pinto; A. Mark Richards; John Lainchbury; Antoni Bayes-Genis; Miquel Santaló; Jordi Ordonez-Llanos; James L. Januzzi

doi:https://doi.org/10.3109/13547501003632580

New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis

Aaron L. Baggish, Roland R. J. van Kimmenade, Yigal Pinto, A. Mark Richards, John Lainchbury, Antoni Bayes-Genis, Miquel Santaló, Jordi Ordonez-Llanos, James L. Januzzi

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Abstract

BACKGROUND: The prognostic value of the New York Heart Association classification (NYHAC) in acutely decompensated heart failure (ADHF) is unknown. OBJECTIVES: We sought to determine the relative value of NYHAC among patients with concomitantly measured amino-terminal pro-B type natriuretic peptide (NT-proBNP) at presentation with ADHF. MATERIALS AND METHODS: NYHAC was determined for 720 patients with ADHF and 1-year mortality status was examined. Cox-proportional hazards analysis compared the prognostic accuracy of NYHAC with other ADHF risk measures. RESULTS: NYHAC had a significant univariate association with 1-year mortality status (HR 1.41, 95% confidence interval (CI) 1.03-1.94; p = 0.03) but was not a significant predictor of death in a multivariable model that included NT-proBNP (HR 2.14; 95% CI 1.65-2.81, p <0.001). CONCLUSIONS: In contrast to objective measures such as NT-proBNP, the NYHAC appears to provide limited prognostic information among individuals with ADHF

Original language	English
Pages (from-to)	307-314
Journal	Biomarkers
Volume	15
Issue number	4
DOIs	https://doi.org/10.3109/13547501003632580
Publication status	Published - 2010

Access to Document

https://doi.org/10.3109/13547501003632580

Cite this

@article{3d70df74cb2e41a2bacb4ae95870f662,

title = "New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis",

abstract = "BACKGROUND: The prognostic value of the New York Heart Association classification (NYHAC) in acutely decompensated heart failure (ADHF) is unknown. OBJECTIVES: We sought to determine the relative value of NYHAC among patients with concomitantly measured amino-terminal pro-B type natriuretic peptide (NT-proBNP) at presentation with ADHF. MATERIALS AND METHODS: NYHAC was determined for 720 patients with ADHF and 1-year mortality status was examined. Cox-proportional hazards analysis compared the prognostic accuracy of NYHAC with other ADHF risk measures. RESULTS: NYHAC had a significant univariate association with 1-year mortality status (HR 1.41, 95% confidence interval (CI) 1.03-1.94; p = 0.03) but was not a significant predictor of death in a multivariable model that included NT-proBNP (HR 2.14; 95% CI 1.65-2.81, p <0.001). CONCLUSIONS: In contrast to objective measures such as NT-proBNP, the NYHAC appears to provide limited prognostic information among individuals with ADHF",

author = "Baggish, {Aaron L.} and {van Kimmenade}, {Roland R. J.} and Yigal Pinto and Richards, {A. Mark} and John Lainchbury and Antoni Bayes-Genis and Miquel Santal{\'o} and Jordi Ordonez-Llanos and Januzzi, {James L.}",

year = "2010",

doi = "https://doi.org/10.3109/13547501003632580",

language = "English",

volume = "15",

pages = "307--314",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis

AU - Baggish, Aaron L.

AU - van Kimmenade, Roland R. J.

AU - Pinto, Yigal

AU - Richards, A. Mark

AU - Lainchbury, John

AU - Bayes-Genis, Antoni

AU - Santaló, Miquel

AU - Ordonez-Llanos, Jordi

AU - Januzzi, James L.

PY - 2010

Y1 - 2010

N2 - BACKGROUND: The prognostic value of the New York Heart Association classification (NYHAC) in acutely decompensated heart failure (ADHF) is unknown. OBJECTIVES: We sought to determine the relative value of NYHAC among patients with concomitantly measured amino-terminal pro-B type natriuretic peptide (NT-proBNP) at presentation with ADHF. MATERIALS AND METHODS: NYHAC was determined for 720 patients with ADHF and 1-year mortality status was examined. Cox-proportional hazards analysis compared the prognostic accuracy of NYHAC with other ADHF risk measures. RESULTS: NYHAC had a significant univariate association with 1-year mortality status (HR 1.41, 95% confidence interval (CI) 1.03-1.94; p = 0.03) but was not a significant predictor of death in a multivariable model that included NT-proBNP (HR 2.14; 95% CI 1.65-2.81, p <0.001). CONCLUSIONS: In contrast to objective measures such as NT-proBNP, the NYHAC appears to provide limited prognostic information among individuals with ADHF

AB - BACKGROUND: The prognostic value of the New York Heart Association classification (NYHAC) in acutely decompensated heart failure (ADHF) is unknown. OBJECTIVES: We sought to determine the relative value of NYHAC among patients with concomitantly measured amino-terminal pro-B type natriuretic peptide (NT-proBNP) at presentation with ADHF. MATERIALS AND METHODS: NYHAC was determined for 720 patients with ADHF and 1-year mortality status was examined. Cox-proportional hazards analysis compared the prognostic accuracy of NYHAC with other ADHF risk measures. RESULTS: NYHAC had a significant univariate association with 1-year mortality status (HR 1.41, 95% confidence interval (CI) 1.03-1.94; p = 0.03) but was not a significant predictor of death in a multivariable model that included NT-proBNP (HR 2.14; 95% CI 1.65-2.81, p <0.001). CONCLUSIONS: In contrast to objective measures such as NT-proBNP, the NYHAC appears to provide limited prognostic information among individuals with ADHF

U2 - https://doi.org/10.3109/13547501003632580

DO - https://doi.org/10.3109/13547501003632580

M3 - Article

C2 - 20370326

SN - 1354-750X

VL - 15

SP - 307

EP - 314

JO - Biomarkers

JF - Biomarkers

IS - 4

ER -